文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

脓毒症患者血小板轨迹变化对预后的影响:基于MIMIC-IV数据库的回顾性分析

PROGNOSTIC IMPLICATIONS OF CHANGES IN PLATELET TRAJECTORIES IN PATIENTS WITH SEPSIS: A RETROSPECTIVE ANALYSIS USING THE MEDICAL INFORMATION MART FOR INTENSIVE CARE IV DATABASE.
PubMed 文献 · Shock · 2024-10-10
一句话结论脓毒症后14天血小板持续低水平与住院、28天及90天死亡风险升高相关,血小板持续显著升高者使用抗血小板药物可能增加死亡风险。

本研究为基于MIMIC-IV数据库的回顾性分析,纳入15,250例脓毒症患者,根据诊断脓毒症后14天内血小板计数变化划分四种轨迹表型:正常水平(表型1)、持续低水平(表型2)、逐渐升高超过正常范围(表型3)、持续显著升高(表型4)。四种表型间28天、住院及90天死亡率差异有统计学意义。多因素回归显示,与表型1相比,表型2住院死亡OR=1.34(95%CI 1.16-1.54)、28天死亡OR=1.69(95%CI 1.47-1.94)、90天死亡OR=1.50(95%CI 1.32-1.69);表型3和4住院死亡无差异,表型4 28天死亡增加(P<0.05),表型3 90天死亡呈下降趋势(P<0.05)。结论提示血小板持续低下与死亡增加相关,中度升高可降低90天死亡率,持续显著升高者使用抗血小板药物或治疗可能增加死亡风险,应谨慎。

要点

  • 脓毒症后14天血小板轨迹分4型:正常(表型1)、持续低(表型2)、渐升至超正常(表型3)、持续显著高(表型4)。
  • 与表型1相比,表型2住院死亡OR=1.34(95%CI 1.16-1.54)、28天死亡OR=1.69(95%CI 1.47-1.94)、90天死亡OR=1.50(95%CI 1.32-1.69)。
  • 表型3与表型4住院死亡与表型1无差异;表型4 28天死亡增加(P<0.05),表型3 90天死亡呈下降趋势(P<0.05)。
  • 逆概率加权回归结果与上述基本一致,仅表型4与表型1的28天死亡无统计学差异。
  • 年龄、体重、抗血小板药物或治疗亚组中,血小板水平与这些因素存在交互作用。

适用人群与场景

  • 脓毒症患者,来自MIMIC-IV数据库,共15,250例用于构建模型。
  • 根据诊断脓毒症后14天内血小板计数变化划分轨迹表型。

诊断标准与关键阈值

  • 血小板轨迹分型:表型1为血小板水平正常;表型2为持续低血小板水平;表型3为逐渐升高超过正常范围;表型4为持续显著升高。

研究设计与关键结果

  • 回顾性分析纳入15,250例脓毒症患者,识别出四种血小板轨迹表型。
  • 四种表型间28天死亡率、住院死亡率和90天死亡率差异有统计学意义。
  • 与表型1相比,表型2住院死亡OR=1.34(95%CI 1.16-1.54)、28天死亡OR=1.69(95%CI 1.47-1.94)、90天死亡OR=1.50(95%CI 1.32-1.69)。
  • 表型3和表型4与表型1相比住院死亡无差异;表型4 28天死亡增加(P<0.05),表型3 90天死亡呈下降趋势(P<0.05)。
  • 逆概率加权回归调整后结果与上述基本一致,仅表型4与表型1的28天死亡无统计学差异。
  • 年龄、体重、抗血小板药物或治疗亚组中,血小板水平与这些因素存在交互作用。

证据类型、等级与局限

  • 研究类型:基于MIMIC-IV数据库的回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,脓毒症患者血小板计数下降与死亡率增加相关,血小板中度升高可降低90天死亡率。
  • 作者建议,对于血小板持续升高的患者,使用抗血小板药物或治疗应谨慎,因其可能增加死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objective: Patients with sepsis often experience reductions or increases in platelet counts, but the implications of these temporal patterns on prognosis remain unclear. The aim of this study was to investigate the impact of changes in platelet trajectories on the clinical prognosis of sepsis. Methods: This study was a retrospective analysis using data from the Medical Information Mart for Intensive Care IV database. Patients with sepsis were identified from the database, and their platelet trajectories were categorized into four distinct models based on the changes in platelet counts over a period of 14 days after diagnosis of sepsis. The effect of these trajectories on patient prognosis was subsequently evaluated. Results: A total of 15,250 patients with sepsis were included to construct a model, and the following four distinct platelet count trajectories were identified: normal platelet levels (phenotype 1); persistently low platelet levels (phenotype 2); gradually increasing platelet levels exceeding the normal range (phenotype 3); and consistently significantly elevated platelet levels (phenotype 4). Statistically significant differences were found in the 28-day mortality, in-hospital mortality, and 90-day mortality among the four phenotypes. Multivariate regression analysis showed that compared to the group with normal platelet levels (phenotype 1), the group with persistently low platelet levels (phenotype 2) had higher in-hospital mortality (odds ratio [OR] = 1.34, 95% confidence interval [CI]: 1.16-1.54), 28-day mortality (OR = 1.69, 95% CI: 1.47-1.94), and 90-day mortality (OR = 1.50, 95% CI: 1.32-1.69). There was no difference in in-hospital mortality between phenotypes 3 and 4 compared to phenotype 1, although phenotype 4 showed an increase in 28-day mortality ( P < 0.05), and phenotype 3 showed a decreasing trend in 90-day mortality ( P < 0.05). The results of inverse probability weighting adjusted by regression were basically consistent with the above findings, except that there was no statistical difference in 28-day mortality between phenotype 4 and phenotype 1. In the subgroups based on age, weight, and antiplatelet drugs or therapies, there was an interaction between platelet levels and these factors. Conclusions: In patients with sepsis, a decrease in platelet count is associated with increased mortality, while a moderate increase in platelet count can reduce 90-day mortality. However, for patients with persistently elevated platelet counts, caution is advised when using antiplatelet drugs or therapies, as it may increase mortality.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Wang Y, Wu J, Shao T, et al. PROGNOSTIC IMPLICATIONS OF CHANGES IN PLATELET TRAJECTORIES IN PATIENTS WITH SEPSIS: A RETROSPECTIVE ANALYSIS USING THE MEDICAL INFORMATION MART FOR INTENSIVE CARE IV DATABASE. Shock. 2024. PMID: 39450919. doi:10.1097/SHK.0000000000002493

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。